Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting April 1, 2019
Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity March 19, 2019
Affimed Announces U.S. Registrational Pathway and Updated Clinical Development Plan for AFM13 at R&D Day December 7, 2018
Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors December 3, 2018
